RT @AAPSComms: #AAPSPT study on ritonavir: In vivo pharmacokinetic comparison bw two dosage forms resulted in equiv exposure w/ approx 20…
RT @AAPSComms: #AAPSPT study on ritonavir: In vivo pharmacokinetic comparison bw two dosage forms resulted in equiv exposure w/ approx 20…
RT @AAPSComms: #AAPSPT study on ritonavir: In vivo pharmacokinetic comparison bw two dosage forms resulted in equiv exposure w/ approx 20…
#AAPSPT study on ritonavir: In vivo pharmacokinetic comparison bw two dosage forms resulted in equiv exposure w/ approx 20% Cmax redux for the KinetiSol tablet. These performance gains were realized w/ a concurrent redux in dosage form mass of 45%. https
#AutismResearchPapers Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet https://t.co/QCpQgmi0fU Paper: https://t.co/NvBsT00SRW
RT @BillTXCeutics: Dan Ellenberger's @UTexasPharmacy new paper @AAPSComms shows KinetiSol Dispersing enables reduction in patient pill burd…
Dan Ellenberger's @UTexasPharmacy new paper @AAPSComms shows KinetiSol Dispersing enables reduction in patient pill burden for ritonavir - reduction in dosage form mass by 45% compared to Norvir! See https://t.co/7wmEYMwPPY.
#AutismResearchPapers Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet https://t.co/QCpQgmi0fU Paper: https://t.co/NvBsT00SRW